Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.

Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers.

The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.

In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection.

Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH.

The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021.

Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.